Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TP53BP2 |
| Gene Name: | TP53BP2 |
| Protein Full Name: | Apoptosis-stimulating of p53 protein 2 |
| Alias: | 53BP2; Apoptosis stimulating of p53 protein 2; ASP2; ASPP2; Bbp; Bcl2-binding protein; P53-binding protein 2; PPP1R13A; Renal carcinoma antigen NY-REN-51; Tumor protein p53 binding protein, 2; Tumor suppressor p53-binding protein 2 |
| Mass (Da): | 125616 |
| Number AA: | 1128 |
| UniProt ID: | Q13625 |
| Locus ID: | 7159 |
| COSMIC ID: | TP53BP2 |
| Gene location on chromosome: | 1q41 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 0.75 |
| Gene undergoes hypermethylation: | HBV-positive hepatocellular carcinoma |
| Normal role description: | Enhances transactivation on the promotors of proapoptotic genes and DNA binding activity of TP53. Important regulator of apoptosis and cell growth. Decreases APPBP1 ability to induce apoptosis. Impedes cell cyle progression at G2 to M transition and seems to play a role in G0/G1 transition as well. DDX42 inhibits proapoptotic activity of TP53BP2. Suggested to interact with several other proteins that are important in cell proliferation and apoptosis. Downregulated expression is associated with cancers and high levels of TP53BP2 with good prognoses. |
| Commentary on involvement of protein in cancer: | No mutations reported on the Atlas of Oncology. |